Trial Outcomes & Findings for Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers (NCT NCT03860207)
NCT ID: NCT03860207
Last Updated: 2023-09-13
Results Overview
Summary of DLTs in DLT evaluable subjects.
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
12 participants
Primary outcome timeframe
Days 1 through 28 in cycle 1
Results posted on
2023-09-13
Participant Flow
Participant milestones
| Measure |
0.009 mcg/kg/Cycle
Dose Level 1 (0.009 mcg/kg/cycle) is the starting dose Phase I Hu3F8-BsAb Dose level 1 (0.009 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.0045 mcg/kg) and 8 (0.0045 mcg/kg) for each cycle.
|
0.09 mcg/kg/Cycle
Phase I Hu3F8-BsAb Dose level 2 (0.09 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.045 mcg/kg) and 8 (0.045 mcg/kg) for each cycle.
|
0.9 mcg/kg/Cycle
Phase I Hu3F8-BsAb Dose level 3 (0.9 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.45 mcg/kg) and 8 (0.45 mcg/kg) for each cycle.
|
2.6 mcg/kg/Cycle
Phase I Hu3F8-BsAb Dose level 4 (2.6 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (1.3 mcg/kg) for each cycle.
|
4.8 mcg/kg/Cycle
Phase I Hu3F8-BsAb Dose level 5 (4.8 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (3.5 mcg/kg) for each cycle.
|
9.3 mcg/kg/Cycle
Phase I Hu3F8-BsAb Dose level 6 (9.3 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (8 mcg/kg) for each cycle.
|
|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
1
|
1
|
1
|
3
|
2
|
3
|
|
Overall Study
Safety Analysis Set
|
1
|
1
|
1
|
3
|
2
|
3
|
|
Overall Study
Discontinued the Treatment
|
1
|
1
|
1
|
3
|
2
|
3
|
|
Overall Study
Discontinued Treatment - Adverse Events
|
0
|
0
|
0
|
0
|
0
|
2
|
|
Overall Study
Discontinued Treatment - Progressive Disease
|
1
|
1
|
1
|
3
|
2
|
1
|
|
Overall Study
COMPLETED
|
1
|
1
|
1
|
2
|
2
|
3
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
1
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
Baseline characteristics by cohort
| Measure |
0.009 mcg/kg/Cycle
n=1 Participants
Phase I Hu3F8-BsAb Dose level 1 (0.009 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.0045 mcg/kg) and 8 (0.0045 mcg/kg) for each cycle.
|
0.09 mcg/kg/Cycle
n=1 Participants
Phase I Hu3F8-BsAb Dose level 2 (0.09 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.045 mcg/kg) and 8 (0.45 mcg/kg) for each cycle.
|
0.9 mcg/kg/Cycle
n=1 Participants
Phase I Hu3F8-BsAb Dose level 3 (0.9 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.45 mcg/kg) and 8 (0.45 mcg/kg) for each cycle.
|
2.6 mcg/kg/Cycle
n=3 Participants
Phase I Hu3F8-BsAb Dose level 4 (2.6 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (1.3 mcg/kg) for each cycle.
|
4.8 mcg/kg/Cycle
n=2 Participants
Phase I Hu3F8-BsAb Dose level 5 (4.8 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (3.5 mcg/kg) for each cycle.
|
9.3 mcg/kg/Cycle
n=3 Participants
Phase I Hu3F8-BsAb Dose level 6 (9.3 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (8 mcg/kg) for each cycle.
|
Total
n=11 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|
|
Age, Customized
0- 6 years
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
|
Age, Customized
7-11 years
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
4 Participants
n=115 Participants
|
|
Age, Customized
12-17 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
|
Age, Customized
18 years and above
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
2 Participants
n=10 Participants
|
4 Participants
n=115 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
4 Participants
n=115 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
7 Participants
n=115 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
11 Participants
n=115 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
9 Participants
n=115 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
|
Region of Enrollment
United States
|
1 participants
n=5 Participants
|
1 participants
n=7 Participants
|
1 participants
n=5 Participants
|
3 participants
n=4 Participants
|
2 participants
n=21 Participants
|
3 participants
n=10 Participants
|
11 participants
n=115 Participants
|
|
Disease Type
High Grade Ostersarcoma
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
2 Participants
n=10 Participants
|
4 Participants
n=115 Participants
|
|
Disease Type
Neuroblastoma
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=10 Participants
|
7 Participants
n=115 Participants
|
PRIMARY outcome
Timeframe: Days 1 through 28 in cycle 1Population: DLT Evaluable Analysis Set
Summary of DLTs in DLT evaluable subjects.
Outcome measures
| Measure |
0.009 mcg/kg/Cycle
n=1 Participants
Phase I Hu3F8-BsAb Dose level 1 (0.009 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.0045 mcg/kg) and 8 (0.0045 mcg/kg) for each cycle.
|
0.09 mcg/kg/Cycle
n=1 Participants
Phase I Hu3F8-BsAb Dose level 2 (0.09 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.045 mcg/kg) and 8 (0.045 mcg/kg) for each cycle.
|
0.9 mcg/kg/Cycle
n=1 Participants
Phase I Hu3F8-BsAb Dose level 3 (0.9 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.45 mcg/kg) and 8 (0.45 mcg/kg) for each cycle.
|
2.6 mcg/kg/Cycle
n=3 Participants
Phase I Hu3F8-BsAb Dose level 4 (2.6 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (1.3 mcg/kg) for each cycle.
|
4.8 mcg/kg/Cycle
n=2 Participants
Phase I Hu3F8-BsAb Dose level 5 (4.8 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (3.5 mcg/kg) for each cycle.
|
9.3 mcg/kg/Cycle
n=3 Participants
Phase I Hu3F8-BsAb Dose level 6 (9.3 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (8 mcg/kg) for each cycle.
|
|---|---|---|---|---|---|---|
|
Dose Limiting Toxicities (DLTs) Phase I
DLT Type - Syncope
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Dose Limiting Toxicities (DLTs) Phase I
Any DLT
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Dose Limiting Toxicities (DLTs) Phase I
DLT Type - Nervous system disorder
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
Adverse Events
0.009 mcg/kg/Cycle
Serious events: 1 serious events
Other events: 1 other events
Deaths: 1 deaths
0.09 mcg/kg/Cycle
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
0.9 mcg/kg/Cycle
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
2.6 mcg/kg/Cycle
Serious events: 1 serious events
Other events: 3 other events
Deaths: 2 deaths
4.8 mcg/kg/Cycle
Serious events: 1 serious events
Other events: 2 other events
Deaths: 2 deaths
9.3 mcg/kg/Cycle
Serious events: 3 serious events
Other events: 3 other events
Deaths: 3 deaths
Serious adverse events
| Measure |
0.009 mcg/kg/Cycle
n=1 participants at risk
Phase I Hu3F8-BsAb Dose level 1 (0.009 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.0045 mcg/kg) and 8 (0.0045 mcg/kg) for each cycle.
|
0.09 mcg/kg/Cycle
n=1 participants at risk
Phase I Hu3F8-BsAb Dose level 2 (0.09 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.045 mcg/kg) and 8 (0.045 mcg/kg) for each cycle.
|
0.9 mcg/kg/Cycle
n=1 participants at risk
Phase I Hu3F8-BsAb Dose level 3 (0.9 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.45 mcg/kg) and 8 (0.45 mcg/kg) for each cycle.
|
2.6 mcg/kg/Cycle
n=3 participants at risk
Phase I Hu3F8-BsAb Dose level 4 (2.6 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (1.3 mcg/kg) for each cycle.
|
4.8 mcg/kg/Cycle
n=2 participants at risk
Phase I Hu3F8-BsAb Dose level 5 (4.8 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (3.5 mcg/kg) for each cycle.
|
9.3 mcg/kg/Cycle
n=3 participants at risk
Phase I Hu3F8-BsAb Dose level 6 (9.3 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (8 mcg/kg) for each cycle.
|
|---|---|---|---|---|---|---|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Nervous system disorders
Nervous system disorder
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Nervous system disorders
Syncope
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
Other adverse events
| Measure |
0.009 mcg/kg/Cycle
n=1 participants at risk
Phase I Hu3F8-BsAb Dose level 1 (0.009 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.0045 mcg/kg) and 8 (0.0045 mcg/kg) for each cycle.
|
0.09 mcg/kg/Cycle
n=1 participants at risk
Phase I Hu3F8-BsAb Dose level 2 (0.09 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.045 mcg/kg) and 8 (0.045 mcg/kg) for each cycle.
|
0.9 mcg/kg/Cycle
n=1 participants at risk
Phase I Hu3F8-BsAb Dose level 3 (0.9 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (0.45 mcg/kg) and 8 (0.45 mcg/kg) for each cycle.
|
2.6 mcg/kg/Cycle
n=3 participants at risk
Phase I Hu3F8-BsAb Dose level 4 (2.6 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (1.3 mcg/kg) for each cycle.
|
4.8 mcg/kg/Cycle
n=2 participants at risk
Phase I Hu3F8-BsAb Dose level 5 (4.8 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (3.5 mcg/kg) for each cycle.
|
9.3 mcg/kg/Cycle
n=3 participants at risk
Phase I Hu3F8-BsAb Dose level 6 (9.3 mcg/kg/cycle) is given IV over \~1-3 hours on Days 1 (1.3 mcg/kg) and 8 (8 mcg/kg) for each cycle.
|
|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Eye disorders
Periorbital oedema
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Eye disorders
Pupils unequal
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Eye disorders
Vision blurred
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Gastrointestinal disorders
Anal incontinence
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
General disorders
Chills
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
General disorders
Face oedema
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
General disorders
Fatigue
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
General disorders
Pain
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
General disorders
Pyrexia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Alanine aminotransferase increased
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Aspartate aminotransferase increased
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Blood fibrinogen decreased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Haemoglobin increased
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
International normalised ratio increased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Lymphocyte count decreased
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Platelet count decreased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
Weight decreased
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Investigations
White blood cell count decreased
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Nervous system disorders
Autonomic nervous system imbalance
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Nervous system disorders
Dizziness
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Nervous system disorders
Headache
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Nervous system disorders
Paraesthesia
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Nervous system disorders
Spinal cord compression
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Psychiatric disorders
Depression
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
1/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
33.3%
1/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
50.0%
1/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Vascular disorders
Hypertension
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
|
Vascular disorders
Hypotension
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
0.00%
0/1 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
66.7%
2/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
2/2 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
100.0%
3/3 • From 1st dose to 30 days after last dose
The table shows TEAEs with onset prior to 31 days after last dose of Hu3F8-BsAb. Treatment Emergent Adverse Event are either events with start date and time after initiation of treatment, or event that may have worsened on or after initiation of treatment. No patients experienced fatal AEs
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place